Pacific Biosciences Of California (PACB) EBITDA Margin (2010 - 2026)

Pacific Biosciences Of California's EBITDA Margin history runs 17 years deep, the most recent figure standing at 23.88% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 112304.0% year-over-year to 23.88%; the TTM figure through Mar 2026 stood at 80.67% (up 35059.0% YoY), while the FY2025 annual figure was 341.45%, down 14040.0% from the prior year.
• EBITDA Margin was 23.88% for Q1 2026 at Pacific Biosciences Of California, up from 90.33% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 3.16% in Q4 2024 to a low of 1146.92% in Q1 2025.
• Historically, EBITDA Margin has averaged 230.6% across 5 years, with a median of 148.39% in 2023.
• The sharpest annual moves came in 2025 and 2026: EBITDA Margin sank 94413 bps in 2025, then soared 112304 bps in 2026.
• A 5-year view of EBITDA Margin shows it stood at 303.03% in 2022, then soared by 55 bps to 137.02% in 2023, then jumped by 102 bps to 3.16% in 2024, then tumbled by 2957 bps to 90.33% in 2025, then soared by 74 bps to 23.88% in 2026.
• The last three EBITDA Margin figures came in at 23.88% (Q1 2026), 90.33% (Q4 2025), and 98.47% (Q3 2025), per Business Quant data.